Drugs / AVX001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05164393 | Nov 2021 → Mar 2022 | actinic keratosis | Coegin Pharma AB | Unknown | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-03-31 | Coegin Pharma AB | Results Coegin Pharma reports positive top-line results from the COAK study, a clinical Phase I/II trial with AVX001 in actinic keratosis coeginpharma.com ↗
Coegin Pharma, a Nordic biotechnology company that, with unique technologies and competencies, develops novel treatments in cancer and inflammatory-driven diseases today reports positive top-line data from its COAK study - a clinical Phase I/II trial in which the safety and tolerability of AVX001 was evaluated in 60 patients with actinic keratosis. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-03-31 | Coegin Pharma AB | Coegin Pharma reports positive top-line results from the COAK study, a clinical Phase I/II trial with AVX001 in actinic keratosis coeginpharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVX001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05164393 ↗ |
| Known as | AKH-217 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095215 ↗ |
| Action | Inhibit | “AVX001, a cytosolic phospholipase A2α (cPLA2α) enzyme inhibitor” PMID 36198452 ↗ Oct 2022 |
| Modality | Small molecule | — CHEMBL5095215 ↗ |
| Route | Topical | “Topical gel treatment for once daily application” NCT05164393 ↗ |